NCT00861380 - Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease | Biotech Hunter

Enrollment

41,188

Participants

Timeline

Start Date

May 4, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

October 5, 2013

Conditions

Infections, StreptococcalStreptococcus Pneumoniae

Interventions

BIOLOGICAL

Pneumococcal conjugate vaccine GSK1024850A

2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination

BIOLOGICAL

GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)

"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination."

BIOLOGICAL

GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)

2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children \>= 12 months of age at the time of first study vaccination.

Trial Locations (1)

00270

GSK Investigational Site, Helsinki